

August 10, 2021

For Immediate Release

Company name: H.U. Group Holdings, Inc.  
 Representative: Shigekazu Takeuchi, Director,  
 President and Group CEO  
 Securities code: 4544 First Section,  
 Tokyo Stock Exchange  
 Contact: Atsuko Murakami,  
 Executive Officer and CFO  
 Telephone No.: +81-3-5909-3337

## Notice of Revisions to Consolidated Earnings Forecasts for the First Six-Month and Full-Year Periods of Fiscal Year Ending March 31, 2022

H.U. Group Holdings, Inc. hereby announces that it has revised its first six-month and full-year consolidated earnings forecasts for the fiscal year ending March 31, 2022, announced on May 14, 2021, in light of its recent business performance. Details are as follows.

### 1. Revisions to consolidated earnings forecasts

#### (1) Forecasts for first six months of fiscal year ending March 31, 2022 (April 1, 2021 – September 30, 2021)

	Net sales (Million yen)	Operating profit (Million yen)	Ordinary profit (Million yen)	Profit attributable to owners of parent (Million yen)	Earnings per share (Yen)	(Reference) EBITDA* (Million yen)
Previously announced forecast (A)	121,000	17,000	18,500	12,500	219.19	23,500
Revised forecast (B)	128,000	21,500	21,000	13,500	236.73	28,000
Change (B - A)	7,000	4,500	2,500	1,000	—	4,500
Change (%)	5.8	26.5	13.5	8.0	—	19.1
(Reference) Results for the same period a year ago (First six months of fiscal year ended March 31, 2021)	98,566	8,146	7,342	5,102	89.52	14,078

#### (2) Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2022 (April 1, 2021 to March 31, 2022)

	Net sales (Million yen)	Operating profit (Million yen)	Ordinary profit (Million yen)	Profit attributable to owners of parent (Million yen)	Earnings per share (Yen)	(Reference) EBITDA* (Million yen)
Previously announced forecast (A)	242,000	25,500	25,500	16,500	289.34	40,500
Revised forecast (B)	249,000	30,000	28,000	17,500	306.87	45,000
Change (B - A)	7,000	4,500	2,500	1,000	—	4,500
Change (%)	2.9	17.6	9.8	6.1	—	11.1
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2021)	223,016	25,392	25,458	17,468	306.38	37,887

\* EBITDA = Operating profit + Depreciation + Amortization of goodwill

## 2. Reasons for revision

The Company has revised its consolidated earnings forecasts as described above, because both net sales and profits for the first six-month and full-year periods of the fiscal year ending March 31, 2022 are expected to exceed the previous forecasts. This chiefly reflects an increase in the number of commissioned PCR tests and greater-than-expected demand for high-sensitivity quantitative antigen test reagents due to the recent increase in the number of COVID-19 infections in Japan, as well as increasing COVID-19 testing demands associated with large-scale events held in Japan over the summer.

## 3. Dividend Forecast

The cash dividend forecast for the fiscal year under review (annual dividend: 125 yen per share) is unchanged from that announced on May 14, 2021.

The earnings forecasts above have been prepared based on information available as of the date on which this material was announced. Actual results may differ due to a variety of factors going forward.

End